Format

Send to

Choose Destination
Clin Immunol. 2015 Nov;161(1):2-10. doi: 10.1016/j.clim.2015.04.005. Epub 2015 Apr 28.

Biomarkers for rheumatoid and psoriatic arthritis.

Author information

1
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
2
Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, UCD, Dublin, Ireland.
3
Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, UCD, Dublin, Ireland. Electronic address: douglas.veale@ucd.ie.

Abstract

Rheumatic diseases, such as rheumatoid and psoriatic arthritis are systemic inflammatory conditions characterized by a chronic form of arthritis, often leading to irreversible joint damage. Early treatment for patients with rheumatic diseases is required to reduce or prevent joint injury. However, early diagnosis can be difficult and currently it is not possible to predict which individual patient will develop progressive erosive disease or who may benefit from a specific treatment according to their clinical features at presentation. Biomarkers are therefore required to enable earlier diagnosis and predict prognosis in both rheumatoid arthritis and psoriatic arthritis. In this review we will examine the evidence and current status of established and experimental biomarkers in rheumatoid and psoriatic arthritis for three important purposes; disease diagnosis, prognosis and prediction of response to therapy.

KEYWORDS:

Autoantibodies; Biomarkers; Psoriatic arthritis; Rheumatoid arthritis; Serological biomarkers; Synovial tissue biomarkers

PMID:
25934385
DOI:
10.1016/j.clim.2015.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center